Dyadic International, Inc

(NASDAQ:DYAI)

Latest On Dyadic International, Inc (DYAI):

Date/Time Type Description Signal Details
2023-05-11 04:07 ESTNewsDyadic International GAAP EPS of -$0.03, revenue of $0.98MN/A
2023-05-11 04:07 ESTNewsDyadic International, Inc. (DYAI) Q1 2023 Earnings Call TranscriptN/A
2023-04-18 22:29 ESTNewsDyadic stock rises on upcoming US patent linked to flu vaccine platformN/A
2023-03-30 03:16 ESTNewsDyadic International GAAP EPS of -$0.34 in-line, revenue of $2.93M misses by $0.72MN/A
2023-03-30 03:15 ESTNewsDyadic International, Inc. (DYAI) Q4 2022 Earnings Call TranscriptN/A
2023-03-12 21:45 ESTNewsDyadic International (DYAI) Presents At BIO CEO & Investor Conference 2023 - SlideshowN/A
2023-03-07 18:38 ESTNewsDyadic gains after update on early-stage trial for COVID booster shotN/A
2023-01-20 05:29 ESTNewsDyadic rises 2%, sells equity interest in AlphazymeN/A
2022-11-11 08:59 ESTNewsDyadic International GAAP EPS of -$0.06 beats by $0.04, revenue of $0.88M misses by $1.02MN/A
2022-11-11 08:59 ESTNewsDyadic International, Inc. (DYAI) Q3 2022 Earnings Call TranscriptN/A
2022-08-11 08:38 ESTNewsDyadic International GAAP EPS of -$0.12 misses by $0.05, revenue of $6.58M beats by $4.18MN/A
2022-08-11 08:38 ESTNewsDyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-13 11:34 ESTNewsDyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 16:30 ESTNewsDyadic International GAAP EPS of -$0.09 beats by $0.05, revenue of $0.65M misses by $0.85MN/A
2022-05-11 22:25 ESTNewsDyadic announces research, license and collaboration to make animal free ingredientsN/A
2022-04-13 16:46 ESTNewsDyadic licensee Epygen Biotech gets India govt funding to develop a COVID-19 shotN/A
2022-03-30 00:38 ESTNewsDyadic International GAAP EPS of -$0.47 misses by $0.09, revenue of $2.4M misses by $5.6MN/A
2022-03-30 00:38 ESTNewsDyadic International's (DYAI) CEO Mark Emalfarb on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-11 02:13 ESTNewsDyadic, Phibro ink license deal to develop animal health vaccineN/A
2022-01-20 18:34 ESTNewsDyadic says C1-cell platform shows potential to develop synthetic cannabinoidsN/A
2021-12-17 21:41 ESTNewsDyadic gains 6% on licensing deal with Janssen to utilize C1 platformN/A
2021-11-11 04:54 ESTNewsDyadic International EPS beats by $0.04, misses on revenueN/A
2021-11-11 04:54 ESTNewsDyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-27 17:25 ESTNewsWarning: DYAI is at high risk of performing badlyN/A
2021-09-21 16:38 ESTNewsDyadic International (DYAI) Presents At H.C. Wainwright 23rd Annual Global Investment Conference - SlideshowN/A
2021-08-13 12:22 ESTNewsDyadic International EPS misses by $0.05, beats on revenueN/A
2021-08-13 12:21 ESTNewsDyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-11 19:38 ESTNewsDyadic stock jumps 22% on licensing deal for DYAI-100 and C1 technology with SorrentoN/A
2021-07-28 03:11 ESTNewsDyadic rises after announcing licensing agreement for COVID-19 vaccine platformN/A
2021-07-21 05:58 ESTNewsDyadic collaborates with Syngene International to develop a COVID-19 vaccine candidateN/A
2021-03-31 00:29 ESTNewsDyadic International EPS beats by $0.01, misses on revenueN/A
2021-03-31 00:29 ESTNewsDyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-23 01:57 ESTNewsDyadic shares surge 45% on COVID-19 vaccine partnership targeting variantsN/A
2020-11-26 19:48 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 03:52 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 11:48 ESTEarnings EstimateAn EPS average of $0.08 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-12 21:56 ESTNewsDyadic International reports Q3 resultsN/A
2020-11-07 15:40 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 12:36 ESTFinancialsCompany financials have been released.Neutral
2020-09-25 17:28 ESTNewsDyadic International (DYAI) Presents At Sidoti Virtual Investor Conference - SlideshowN/A
2020-09-18 02:50 ESTNewsDyadic teams up with Jiangsu Hengrui for biologic drug developmentN/A
2020-09-17 04:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-27 04:32 ESTAnalyst RatingThe Analyst Target Price has decreased from $11.67 to $11.Neutral
2020-08-15 21:44 ESTNewsDyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-15 00:37 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 17:26 ESTNewsDyadic International EPS misses by $0.03, beats on revenueN/A
2020-08-14 08:38 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 00:50 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:51 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 10:28 ESTNewsDyadic announces two new fully funded collaborationsN/A

About Dyadic International, Inc (DYAI):

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. The company also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

See Advanced Chart

General

  • Name Dyadic International, Inc
  • Symbol DYAI
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 6
  • Fiscal Year EndDecember
  • IPO Date2004-11-05
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryLife Sciences Tools & Services
  • Web URLhttp://www.dyadic.com
View More

Valuation

  • Forward PE 14.47
  • Price/Sales (Trailing 12 Mt.) 89.29
  • Price/Book (Most Recent Quarter) 5.04
  • Enterprise Value Revenue 71.48
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.07
  • Operating Margin -572%
  • Return on Assets -17%
  • Return on Equity -27%
  • Revenue 1.69 million
  • Earnings Per Share -$0.26
  • Revenue Per Share $0.06
  • Gross Profit 221375
  • Quarterly Earnings Growth -8.4%
View More

Highlights

  • Market Capitalization 130.54 million
  • PE Ratio -7.16
  • Analyst Target Price $11
  • Book Value Per Share $1.09
View More

Share Statistics

  • Shares Outstanding 27.48 million
  • Shares Float 17.92 million
  • % Held by Insiders 3005%
  • % Held by Institutions 24.88%
  • Shares Short 692115
  • Shares Short Prior Month 749039
  • Short Ratio 5.68
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 0.05
  • 52 Week High $10.98
  • 52 Week Low $3.71
  • 50 Day Moving Average 5.61
  • 200 Day Moving Average 6.37
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Dyadic International, Inc (DYAI) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Dyadic International, Inc (DYAI) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$N/A-$0.09-$0.07-28.57%
2020-06-302020-08-13$N/A-$0.10-$0.07-42.86%
2020-03-312020-05-14$315372-$0.08-$0.02-300%
2019-12-312020-03-30$433168-$0.07-$0.070%
2019-09-302019-11-13$454507-$0.06-$0.0714.29%
2019-06-302019-08-13$390874-$0.10-$0.07-42.86%
2019-03-312019-05-09$402527-$0.08
2018-12-312019-03-27$686875-$0.02-$0.0666.67%
2018-09-302018-11-07$262960-$0.06-$0.060%
2018-06-302018-08-09$161286-$0.06
2018-03-312018-05-11$184330-$0.07
2017-12-312018-03-28$157000-$0.05
2017-09-302017-11-10$272000-$0.05
2017-06-302017-08-11$207000-$0.05
2017-03-312017-05-12$122000$0.07
2016-12-312017-03-16$491000-$0.06
2016-09-302016-11-11$N/A-$0.03
2016-06-302016-08-12$15000$0.01
2016-03-312016-05-13$87000-$0.02
2015-12-312016-03-30$30000$1.61
2015-09-302015-11-13$213000$0.06
2015-06-302015-08-17$35000-$0.01
2015-03-312015-05-15$38000-$0.01
2014-12-312015-03-12$113000-$0.05
2014-09-302014-11-14$N/A-$0.03
2014-06-302014-08-15$N/A-$0.05
2014-03-312014-05-09$N/A-$0.05
2013-12-312014-03-14$4.11 million-$0.02
2013-09-302013-11-15$3.46 million-$0.05
2013-06-302013-08-09$7.08 million$0.10
2013-03-312013-05-16$2.48 million-$0.05
2012-12-312013-03-08$2.71 million-$0.04
2012-09-302012-11-09$2.52 million-$0.01
2012-06-302012-08-14$7.85 million$0.12
2012-03-312012-05-11$2.52 million-$0.02
2011-12-312012-03-28$2.39 million-$0.04
2011-09-302011-11-04$2.58 million-$0.04
2011-06-302011-08-05$2.99 million-$0.02
2011-03-312011-05-05$2.3 million-$0.05
2010-12-312011-03-10$2.25 million-$0.05
2010-09-302010-11-15$1.99 million-$0.04
2010-06-302010-08-13$2.21 million-$0.05
2010-03-312010-05-17$2 million-$0.04
2009-12-312010-03-03$2.45 million-$0.15
2009-09-302009-11-16$2.09 million-$0.02
2009-03-312009-05-11$4.98 million$0.07
2007-03-312007-04-02$N/A-$0.12-$0.09-33.33%
2006-09-302006-11-09$4.21 million-$0.10-$0.100%
2006-06-302006-08-11$3.97 million-$0.13-$0.08-62.5%
2006-03-312006-05-15$3.83 million-$0.10-$0.09-11.11%
2005-12-312006-03-29$4.02 million-$0.12-$0.09-33.33%
2005-09-302005-11-14$4.14 million-$0.11-$0.09-22.22%
2005-06-302005-08-11$3.99 million-$0.10
2005-03-312005-05-17$3.73 million-$0.14

Dyadic International, Inc (DYAI) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Dyadic International, Inc (DYAI) Chart:

Dyadic International, Inc (DYAI) News:

Below you will find a list of latest news for Dyadic International, Inc (DYAI) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Dyadic International, Inc (DYAI) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-04-192.50.05CALL0 114402.11FALSE00
2024-04-1950CALL0 00FALSE00
2024-04-197.50CALL0 00FALSE00
2024-04-192.50PUT0 01027.36TRUE00
2024-04-1950PUT0 01438.94TRUE00
2024-04-197.50PUT0 01483.07TRUE00
2024-05-172.50.07CALL0 206139.04FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-172.50PUT0 0258.56TRUE00
2024-05-1750PUT0 0343.83TRUE00
2024-05-177.50PUT0 0656.65TRUE00
2024-08-162.50.1CALL0 420FALSE00
2024-08-1650CALL0 00FALSE00
2024-08-167.50CALL0 00FALSE00
2024-08-162.51.17PUT0 9108.92TRUE00
2024-08-1650PUT0 0409.5TRUE00
2024-08-167.50PUT0 0346.62TRUE00
2024-11-152.50CALL0 00FALSE00
2024-11-1550CALL0 00FALSE00
2024-11-157.50CALL0 10FALSE00
2024-11-152.50PUT0 0287.86TRUE00
2024-11-1550PUT0 0146.63TRUE00
2024-11-157.50PUT0 0241.96TRUE00

Latest DYAI Trades:

Date Shares Price
Jun 13, 2022 7:36 PM EST100$2.37

Dyadic International, Inc (DYAI) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000027/0001213809-20-000027-index.htm
2020-08-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1213809/000000000020007840/0000000000-20-007840-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1213809/000106299320001007/0001062993-20-001007-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000044/0001213809-19-000044-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000047/0001213809-19-000047-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000048/0001213809-19-000048-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000049/0001213809-19-000049-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000052/0001213809-19-000052-index.htm
2019-07-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000054/0001213809-19-000054-index.htm
2019-07-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000057/0001213809-19-000057-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1213809/000121380919000061/0001213809-19-000061-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000063/0001213809-19-000063-index.htm
2019-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000065/0001213809-19-000065-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000067/0001213809-19-000067-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000069/0001213809-19-000069-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000071/0001213809-19-000071-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000072/0001213809-19-000072-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000073/0001213809-19-000073-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1213809/000121380919000074/0001213809-19-000074-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000075/0001213809-19-000075-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000076/0001213809-19-000076-index.htm
2019-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380919000077/0001213809-19-000077-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000001/0001213809-20-000001-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000002/0001213809-20-000002-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000003/0001213809-20-000003-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000004/0001213809-20-000004-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000005/0001213809-20-000005-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000006/0001213809-20-000006-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000007/0001213809-20-000007-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000008/0001213809-20-000008-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000009/0001213809-20-000009-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000010/0001213809-20-000010-index.htm
2020-01-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000011/0001213809-20-000011-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000013/0001213809-20-000013-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000014/0001213809-20-000014-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000016/0001213809-20-000016-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000017/0001213809-20-000017-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1213809/000121380920000018/0001213809-20-000018-index.htm
2020-05-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000020/0001213809-20-000020-index.htm
2020-05-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000022/0001213809-20-000022-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000023/0001213809-20-000023-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1213809/000121380920000024/0001213809-20-000024-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000026/0001213809-20-000026-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000027/0001213809-20-000027-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1213809/000121380920000028/0001213809-20-000028-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000030/0001213809-20-000030-index.htm
2020-08-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1213809/000121380920000032/0001213809-20-000032-index.htm
2020-08-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000033/0001213809-20-000033-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1213809/000121380920000034/0001213809-20-000034-index.htm
2020-08-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1213809/999999999520002250/9999999995-20-002250-index.htm

Dyadic International, Inc (DYAI) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dyadic International, Inc (DYAI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3005%
Institutional Ownership: 2488%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-12-03Barry BucklandDirectorSell15,000.006.1892,700.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000076/0001213809-19-000076-index.htm
2019-07-10RONEN TCHELETVP of Research and Bus. DvlpmtSell10,000.005.8758,700.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000057/0001213809-19-000057-index.htm
2019-08-12RONEN TCHELETVP of Research and Bus. DvlpmtSell3,700.005.7221,164.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000065/0001213809-19-000065-index.htm
2019-08-13RONEN TCHELETVP of Research and Bus. DvlpmtSell6,300.005.7536,225.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000065/0001213809-19-000065-index.htm
2019-09-10RONEN TCHELETVP of Research and Bus. DvlpmtSell10,000.005.2752,700.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000067/0001213809-19-000067-index.htm
2019-10-10RONEN TCHELETVP of Research and Bus. DvlpmtSell4,782.006.0428,883.280.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000069/0001213809-19-000069-index.htm
2019-10-11RONEN TCHELETVP of Research and Bus. DvlpmtSell5,218.006.0831,725.440.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000069/0001213809-19-000069-index.htm
2019-11-11RONEN TCHELETVP of Research and Bus. DvlpmtSell10,000.005.9959,900.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000071/0001213809-19-000071-index.htm
2019-12-11RONEN TCHELETVP of Research and Bus. DvlpmtSell4,575.005.8026,535.000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000077/0001213809-19-000077-index.htm
2019-07-10RONEN TCHELETVP of Research and Bus. DvlpmtBuy10,000.001.4114,100.0010,000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000057/0001213809-19-000057-index.htm
2019-09-10RONEN TCHELETVP of Research and Bus. DvlpmtBuy10,000.001.4114,100.0010,000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000067/0001213809-19-000067-index.htm
2019-11-11RONEN TCHELETVP of Research and Bus. DvlpmtBuy10,000.001.4114,100.0010,000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000071/0001213809-19-000071-index.htm
2019-12-11RONEN TCHELETVP of Research and Bus. DvlpmtBuy4,575.001.416,450.7510,000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000077/0001213809-19-000077-index.htm
2019-12-03Barry BucklandDirectorBuy12,500.001.3917,375.0012,500.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000076/0001213809-19-000076-index.htm
2019-12-03Barry BucklandDirectorBuy2,500.001.393,475.0015,000.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000076/0001213809-19-000076-index.htm
2019-08-12RONEN TCHELETVP of Research and Bus. DvlpmtBuy3,700.001.415,217.003,700.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000065/0001213809-19-000065-index.htm
2019-12-10RONEN TCHELETVP of Research and Bus. DvlpmtSell5,425.005.8431,682.004,575.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000077/0001213809-19-000077-index.htm
2019-10-10RONEN TCHELETVP of Research and Bus. DvlpmtBuy4,782.001.416,742.624,782.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000069/0001213809-19-000069-index.htm
2019-10-11RONEN TCHELETVP of Research and Bus. DvlpmtBuy5,218.001.417,357.385,218.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000069/0001213809-19-000069-index.htm
2019-12-10RONEN TCHELETVP of Research and Bus. DvlpmtBuy5,425.001.417,649.255,425.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000077/0001213809-19-000077-index.htm
2019-08-13RONEN TCHELETVP of Research and Bus. DvlpmtBuy6,300.001.418,883.006,300.00https://www.sec.gov/Archives/edgar/data/1213809/000121380919000065/0001213809-19-000065-index.htm